Having access to a technology that universally clots all blood samples within five minutes will contribute to improved patient outcomes and reduced healthcare costs
Q-Sera, an Australian venture-backed company, has announced a partnership with Terumo Corporation, the leading Japanese medical device company, which will see its patent protected RAPClot™ rapid serum tube technology manufactured and used in Japan.
RAPClot™ serum tubes (evacuated blood collection tubes) produce high quality serum in less than five minutes, reducing the turnaround time from sample collection to serum analysis compared with current technologies.
RAPClot™ is also effective in producing high quality serum from blood samples that contain anti-coagulants such as heparin. The ability of RAPClot™ tubes to generate high quality serum in less than 5 minutes and to clot anti-coagulated blood samples represents a substantial step forward in patient diagnosis.
Under the terms of the partnership, Terumo Corporation has been granted the exclusive rights to manufacture and market Q-Sera's rapid serum tube technology in Japan. Q-Sera will also supply Terumo Corporation with the recombinant protein RAPClot™.
Is Singapore ready to becom...
Laboratories in times of so...
The lasting benefits of decentraliz
For the automation portfolio, we se
Is Singapore ready to become a glob
India develops AI tool to detect CO
China focuses on next-generation in
BioNTech to establish first South E
WHO lists China's Sinopharm COVID-1
Is APAC focusing on vigilance & preparedness for new & existing infectious diseases?
1 North Bridge Road, #08-08 High Street Centre, Singapore 179094 Email : communications@mmactiv.com
© 2021 MM Activ Sci-Tech Communications. All rights reserved | Disclaimer
Web Interface Conceived and Powered By : SCI Knowledge Interlinks